The highly mature type 2 diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will see pharmaceutical companies prioritizing competitive pricing in order to offset the impact of patent expiries ahead of improving existing products, new research indicates.
According to research and consulting firm GlobalData’ latest report, human insulins and many insulin analogs are currently off patent or will soon lose their patents. The patents for Humulin and Novolin expired in 2001 and 2002, respectively. More recent patent losses include Eli Lilly’s (NYSE: LLY) Humalog (insulin lispro) in 2013, Novo Nordisk’s (NOV: N) NovoLog/NovoRapid (insulin aspart) in 2014, and Sanofi’s (Euronext: SAN) Lantus (insulin glargine) in 2014–2015. Lantus is already beginning to suffer erosion to the first to market insulin biosimilar, Eli Lilly’s Abasaglar (insulin glargine).
Lyxumia heavily discounted
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze